Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

Allogene Therapeutics (ALLO) incurred a loss of 28 cents per share in fourth-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 34 cents. In the year-ago period, the company had incurred a loss of 51 cents per share.See the Zacks Earnings Calendar to stay ahead of market-making news.ALLO did not generate revenues during the reported quarter. The Zacks Consensus Estimate for fourth-quarter sales was pegged at $0.07 million. In the year-ago period, the company recorded revenues of$0.02 mil ...